June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A model of allergic conjunctivitis in transgenic mice with humanized FcεRIα
Author Affiliations & Notes
  • Kaspar Werner Schürch
    Ophthalmology Department, Bern University Hospital, Bern, Switzerland
  • Andreas Ebneter
    Ophthalmology Department, Bern University Hospital, Bern, Switzerland
  • Chantal Dysli
    Ophthalmology Department, Bern University Hospital, Bern, Switzerland
  • Alexander Eggel
    Immunology Department, Bern University Hospital, Bern, Switzerland
  • Martin Zinkernagel
    Ophthalmology Department, Bern University Hospital, Bern, Switzerland
  • Footnotes
    Commercial Relationships Kaspar Schürch, None; Andreas Ebneter, Bayer (R); Chantal Dysli, None; Alexander Eggel, None; Martin Zinkernagel, Heidelberg Engineering (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4879. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kaspar Werner Schürch, Andreas Ebneter, Chantal Dysli, Alexander Eggel, Martin Zinkernagel; A model of allergic conjunctivitis in transgenic mice with humanized FcεRIα. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4879. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Allergy has an increasing prevalence and severity especially in industrialized countries. The spectrum of allergic symptoms ranges from allergic rhinitis to dermatitis to allergic conjunctivitis. Allergic conjunctivitis is an immunoglobulin E (IgE)-mediated type I allergic reaction. Because IgE is the central molecule responsible for allergic reactions, neutralizing IgE or inhibiting the IgE synthesis represents a rational approach for the treatment. We present a transgenic mouse model for allergic conjunctivitis using mice expressing a humanized high-affinity IgE receptor (B.6Cg-Fce1a(tm1Knt)Tg(FcERIa)1Bhk/J).

Methods: Tg(FcεRIα) transgenic mice and controls were injected with subconjunctival NIP specific human-IgE (JW8, 100 nM in PBS) with subsequent intravenous allergen challenge with NIP (NIP25-BSA, 1.5 mg/ml in Saline). Allergic reaction was quantified in vivo using spectral domain anterior segment OCT (Heidelberg Engineering) and ex vivo using immunohistochemistry for monoclonal rabbit anti-mouse mast cell tryptase, polyclonal rabbit anti-human IgE and FcεRIα and HE staining.

Results: The transgenic FcεRIα group showed a statistically significant (p<0.05) swelling of the conjunctiva using anterior segment OCT compared to the control group. The IgE binding was confirmed by immunohistochemistry which was co-localized to tryptase positive and FcεRIα positive mast cells.

Conclusions: We present the preliminary results of a novel mouse model for allergic conjunctivitis using a transgenic mouse with a humanized FcεRIα receptor and quantify the allergic reactions using anterior segment OCT in vivo. This model will be helpful to dissect immunological pathways in allergic conjunctivitis and may be useful to develop novel therapeutic options for this common disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×